GLP1R and polycystic ovary syndrome: GLP-1 receptor agonists (GLP-1RAs) such as liraglutide, exenatide, and semaglutide have emerged as novel therapeutic prospects for PCOS, owing to their distinct advantages in treating metabolic disorders.